Shaping the Treatment Landscape in Myelodysplastic Syndromes and Acute Myeloid Leukemia - report from EHA2025
Professor Gail Roboz shares her insights on the treatment landscape in myelodysplastic syndromes and acute myeloid leukemia at the 2025 EHA Annual Meeting.
Video: https://medicaldigest.org/scientific-contents/interview:shaping-treatment-landscape-myelodysplastic-syndromes-and-acute-myeloid-leukemia
How I Treat series on Acute Myeloid Leukemia
In this episode, Associate Blood editor Dr. Selina Luger leads a discussion with Drs. Courtney DiNardo, Eunice Wang, Andrew Wei and Gail Roboz about the advances in treatment options for Acute Myeloid Leukemia (AML). The conversation highlights new combinations like Venetoclax-azacitidine, challeng…
Key Insights from ASH 2025
In this episode of CancerCast, Dr. Manish Shah is joined by Drs. Gail Roboz and Rick Furman, two internationally renowned Weill Cornell leaders in advancing therapies for leukemia and lymphoma, to preview groundbreaking research from the 2025 American Society of Hematology (ASH) Annual Meeting. Dr…
Treating elderly or unfit patients with AML: current approach and future directions
This episode of the VJHemOnc podcast focuses on the treatment of elderly or unfit patients with acute myeloid leukemia (AML). Featuring experts Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, Marina Konop…
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight int…
ASH 2025 | Pivekimab sunirine + Ven + Aza in unfit patients with ND CD123+ AML: Phase Ib/II efficacy and safety
Following the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What are the latest findings from clinical trials of pivekimab sunirine in unfit …
S7 Ep11: Treating Together: Navigating Treatment Decisions in Relapsed NPM1-Mutant AML: Practical Insights for Clinical Care
Dr Gabriel Mannis from Stanford University and Dr Gail Roboz from Weill Cornell Medicine discussed the evolving treatment landscape for relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). The conversation highlighted the dramatic transformation of relapsed/refractory AML management from…
Managing side effects of menin inhibitors in clinical practice
The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What side effects are typically observed with menin inhibitor-based regimens, and how do you approach managing them in clinical practice?
Roboz provides an overview of the key toxicities associated wi…
Improving Treatment Strategies in Acute Myeloid Leukemia (AML)
Treatment for acute myeloid leukemia (AML), an aggressive blood cancer that affects the bone marrow and disrupts normal blood cell production, has advanced significantly over the past decade. On this episode of CancerCast, Dr. Manish Shah speaks with Dr. Gail Roboz, Director of the Clinical and Tr…
팟캐스트 검색 엔진
당사 웹사이트를 사용하여3,831,088팟캐스트 및196,732,836에피소드를 사람, 장소 또는 주제별로 검색할 수 있습니다.
지식에 대한 투자가 가장 큰 이익을 주기에 저는 팟캐스트를 듣습니다.
‐ Benjamin "Llamacorn" Franklin
